These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 12924539)

  • 1. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor.
    Domingo P; Sambeat MA; Pérez A; Ordoñez J; Rodriguez J; Vázquez G
    Antivir Ther; 2003 Jun; 8(3):223-31. PubMed ID: 12924539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.
    Saint-Marc T; Partisani M; Poizot-Martin I; Bruno F; Rouviere O; Lang JM; Gastaut JA; Touraine JL
    AIDS; 1999 Sep; 13(13):1659-67. PubMed ID: 10509567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
    Carr A; Workman C; Smith DE; Hoy J; Hudson J; Doong N; Martin A; Amin J; Freund J; Law M; Cooper DA;
    JAMA; 2002 Jul; 288(2):207-15. PubMed ID: 12095385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
    Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
    HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
    John M; McKinnon EJ; James IR; Nolan DA; Herrmann SE; Moore CB; White AJ; Mallal SA
    J Acquir Immune Defic Syndr; 2003 May; 33(1):29-33. PubMed ID: 12792352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy.
    van der Valk M; Casula M; Weverlingz GJ; van Kuijk K; van Eck-Smit B; Hulsebosch HJ; Nieuwkerk P; van Eeden A; Brinkman K; Lange J; de Ronde A; Reiss P
    Antivir Ther; 2004 Jun; 9(3):385-93. PubMed ID: 15259901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.
    Saint-Marc T; Partisani M; Poizot-Martin I; Rouviere O; Bruno F; Avellaneda R; Lang JM; Gastaut JA; Touraine JL
    AIDS; 2000 Jan; 14(1):37-49. PubMed ID: 10714566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.
    Joly V; Flandre P; Meiffredy V; Leturque N; Harel M; Aboulker JP; Yeni P
    AIDS; 2002 Dec; 16(18):2447-54. PubMed ID: 12461419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy.
    Sievers M; Walker UA; Sevastianova K; Setzer B; Wågsäter D; Eriksson P; Yki-Järvinen H; Sutinen J
    J Infect Dis; 2009 Jul; 200(2):252-62. PubMed ID: 19519254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
    Guaraldi G; Zona S; Orlando G; Carli F; Stentarelli C; Luzi K; Garlassi E; Menozzi M; Bagni P; Adorni F
    Clin Drug Investig; 2011 Nov; 31(11):759-67. PubMed ID: 21919542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.
    van Vonderen MG; van Agtmael MA; Hassink EA; Milinkovic A; Brinkman K; Geerlings SE; Ristola M; van Eeden A; Danner SA; Reiss P;
    PLoS One; 2009 May; 4(5):e5647. PubMed ID: 19479079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Aurpibul L; Puthanakit T; Taejaroenkul S; Sirisanthana T; Sirisanthana V
    Pediatr Infect Dis J; 2012 Apr; 31(4):384-8. PubMed ID: 22124211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Tenofovir as a strategy to avoid or limit adverse effects].
    Portilla J
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():19-24. PubMed ID: 19195434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
    Martin A; Smith DE; Carr A; Ringland C; Amin J; Emery S; Hoy J; Workman C; Doong N; Freund J; Cooper DA;
    AIDS; 2004 Apr; 18(7):1029-36. PubMed ID: 15096806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.
    Jones SP; Qazi N; Morelese J; Lebrecht D; Sutinen J; Yki-Jărvinen H; Back DJ; Pirmohamed M; Gazzard BG; Walker UA; Moyle GJ
    J Acquir Immune Defic Syndr; 2005 Dec; 40(5):565-72. PubMed ID: 16284533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stavudine versus zidovudine and the development of lipodystrophy.
    Bogner JR; Vielhauer V; Beckmann RA; Michl G; Wille L; Salzberger B; Goebel FD
    J Acquir Immune Defic Syndr; 2001 Jul; 27(3):237-44. PubMed ID: 11464142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
    McComsey GA; Ward DJ; Hessenthaler SM; Sension MG; Shalit P; Lonergan JT; Fisher RL; Williams VC; Hernandez JE;
    Clin Infect Dis; 2004 Jan; 38(2):263-70. PubMed ID: 14699460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.
    Mercier S; Gueye NF; Cournil A; Fontbonne A; Copin N; Ndiaye I; Dupuy AM; Cames C; Sow PS; Ndoye I; Delaporte E; Simondon KB
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):224-30. PubMed ID: 19339897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.